Effect of reduced versus usual lipid emulsion dosing on bilirubin neurotoxicity and neurodevelopmental impairment in extremely preterm infants: study protocol for a randomized controlled trial

Lindsay F Holzapfel, Cody Arnold, Jon E Tyson, Steven M Shapiro, Eric W Reynolds, Claudia Pedroza, Emily K Stephens, Alan Kleinfeld, Andrew H Huber, Matthew A Rysavy, Maria Del Mar Romero Lopez, Amir M Khan, Lindsay F Holzapfel, Cody Arnold, Jon E Tyson, Steven M Shapiro, Eric W Reynolds, Claudia Pedroza, Emily K Stephens, Alan Kleinfeld, Andrew H Huber, Matthew A Rysavy, Maria Del Mar Romero Lopez, Amir M Khan

Abstract

Background: Bilirubin neurotoxicity (BN) occurs in premature infants at lower total serum bilirubin levels than term infants and causes neurodevelopmental impairment. Usual dose lipid infusions in preterm infants may increase free fatty acids sufficiently to cause bilirubin displacement from albumin, increasing passage of unbound bilirubin (UB) into the brain leading to BN and neurodevelopmental impairment not reliably identifiable in infancy. These risks may be influenced by whether cycled or continuous phototherapy is used to control bilirubin levels.

Objective: To assess differences in wave V latency measured by brainstem auditory evoked responses (BAER) at 34-36 weeks gestational age in infants born ≤ 750 g or < 27 weeks' gestational age randomized to receive usual or reduced dose lipid emulsion (half of the usual dose) irrespective of whether cycled or continuous phototherapy is administered.

Methods: Pilot factorial randomized controlled trial (RCT) of lipid dosing (usual and reduced) with treatment groups balanced between cycled or continuous phototherapy assignment. Eligible infants are born at ≤ 750 g or < 27 weeks' gestational age enrolled in the NICHD Neonatal Research Network RCT of cycled or continuous phototherapy. Infants will randomize 1:1 to reduced or usual dose lipid assignment during the first 2 weeks after birth and stratified by phototherapy assignment. Free fatty acids and UB will be measured daily using a novel probe. BAER testing will be performed at 34-36 weeks postmenstrual age or prior to discharge. Blinded neurodevelopmental assessments will be performed at 22-26 months. Intention-to-treat analyses will be performed with generalized linear mixed models with lipid dose and phototherapy assignments as random effects covariates, and assessment for interactions. Bayesian analyses will be performed as a secondary analysis.

Discussion: Pragmatic trials are needed to evaluate whether lipid emulsion dosing modifies the effect of phototherapy on BN. This factorial design presents a unique opportunity to evaluate both therapies and their interaction. This study aims to address basic controversial questions about the relationships between lipid administration, free fatty acids, UB, and BN. Findings suggesting a reduced lipid dose can diminish the risk of BN would support the need for a large multicenter RCT of reduced versus usual lipid dosing.

Trial registration: Clinical Trials.gov, NCT04584983, Registered 14 October 2020, https://ichgcp.net/clinical-trials-registry/NCT04584983 Protocol version: Version 3.2 (10/5/2022).

Keywords: Bilirubin neurotoxicity; Brainstem auditory evoked responses; Extremely preterm infants; Lipid emulsions; Neurodevelopmental impairment; Phototherapy; Randomized controlled trial.

Conflict of interest statement

The authors declare no competing interests.

© 2023. The Author(s).

Figures

Fig. 1
Fig. 1
Patient flow diagram

References

    1. Hay WW., Jr Aggressive Nutrition of the Preterm Infant. Curr Pediatr Rep. 2013;1(4):1–17. doi: 10.1007/s40124-013-0026-4.
    1. Simmer K, Rao SC. Early introduction of lipids to parenterally-fed preterm infants. Cochrane Database Syst Rev. 2005;(2). [Cited 2020 Jul 6] .
    1. Lapillonne A, Fidler Mis N, Goulet O, van den Akker CHP, Wu J, Koletzko B, et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Lipids. Clin Nutr. 2018;37(6):2324–2336. doi: 10.1016/j.clnu.2018.06.946.
    1. Prasertsom W, Phillipos EZ, Van Aerde JE, Robertson M. Pulmonary vascular resistance during lipid infusion in neonates. Arch Dis Child. 1996;74(2 SUPPL.):95–98. doi: 10.1136/fn.74.2.F95.
    1. Skouroliakou M, Konstantinou D, Agakidis C, Kaliora A, Kalogeropoulos N, Massara P, et al. Parenteral MCT/ω-3 Polyunsaturated Fatty Acid-Enriched Intravenous Fat Emulsion is Associated with Cytokine and Fatty Acid Profiles Consistent with Attenuated Inflammatory Response in Preterm Neonates: A Randomized. Double-Blind Clinical Trial Nutr Clin Pract. 2016;31(2):235–244. doi: 10.1177/0884533615602011.
    1. Amin SB. Effect of Free Fatty Acids on Bilirubin-Albumin Binding Affinity and Unbound Bilirubin in Premature Infants. J Parenter Enter Nutr. 2010;34(4):414–20. doi: 10.1177/0148607110362529.
    1. Hegyi T, Kleinfeld A, Huber A, Weinberger B, Memon N, Shih WJ, et al. Effects of Soybean Lipid Infusion on Unbound Free Fatty Acids and Unbound Bilirubin in Preterm Infants. J Pediatr. 2017;184:45–50.e1.10.1016/j.jpeds.2016.12.026.
    1. Amin SB, Maisels MJ, Watchko JF. Early Lipid Infusions and Unbound Bilirubin in Preterm Neonates: A Cause for Concern? Vol. 184, J Pediatrics. Mosby Inc.; 2017.6–7.
    1. Oh W, Stevenson DK, Tyson JE, Morris BH, Ahlfors CE, Bender GJ, et al. Influence of clinical status on the association between plasma total and unbound bilirubin and death or adverse neurodevelopmental outcomes in extremely low birth weight infants. Acta Paediatr Int J Paediatr. 2010;99(5):673–678. doi: 10.1111/j.1651-2227.2010.01688.x.
    1. Shapiro SM, Nakamura H. Bilirubin and the auditory system. J Perinatol. 2001;21:S52–S55. doi: 10.1038/sj.jp.7210635.
    1. Shapiro SM, Popelka GR. Auditory Impairment in Infants at Risk for Bilirubin-Induced Neurologic Dysfunction. 2011.
    1. Wennberg RP, Ahlfors CE, Bickers R, McMurtry CA, Shetter JL. Abnormal auditory brainstem response in a newborn infant with hyperbilirubinemia: Improvement with exchange transfusion. J Pediatr. 1982;100(4):624–626. doi: 10.1016/S0022-3476(82)80771-3.
    1. Kuriyama M, Tomiwa K, Konishi Y, Mikawa H. Original Artides Improvement in Auditory Bminstem Response of Hyperbilimbinemic Infants After Exchange Transfusions. Pediatr Neurol. 1986;2(3):127–132. doi: 10.1016/0887-8994(86)90002-0.
    1. Morris BH, Oh W, Tyson JE, Stevenson DK, Phelps DL, O’Shea TM, et al. Aggressive vs. Conservative Phototherapy for Infants with Extremely Low Birth Weight. N Engl J Med. 2008;359(18):1885–96.
    1. Lasky RE, Church MW, Orlando MS, Morris BH, Parikh NA, Tyson JE, et al. The effects of aggressive vs. conservative phototherapy on the brainstem auditory evoked responses of extremely-low-birth-weight infants. Pediatr Res. 2012;71(1):77–84. [Cited 2020 Jul 6] .
    1. Ahlfors CE, Amin SB, Parker AE. Unbound bilirubin predicts abnormal automated auditory brainstem response in a diverse newborn population. J Perinatol. 2009;29(4):305–309. doi: 10.1038/jp.2008.199.
    1. Arnold C, Pedroza C, Tyson JE. Phototherapy in ELBW newborns: Does it work? Is it safe? The evidence from randomized clinical trials. Semin Perinatol. 2014;38(7):452–64.10.1053/j.semperi.2014.08.008.
    1. Stevenson DK, Wong RJ, Arnold CC, Pedroza C, Tyson JE. Phototherapy and the Risk of Photo-Oxidative Injury in Extremely Low Birth Weight Infants. Clin Perinatol. 2016;43(2):291–295. doi: 10.1016/j.clp.2016.01.005.
    1. Arnold C, Tyson JE, Pedroza C, Carlo WF, Stevenson DK, Wong R, et al. Cycled Phototherapy Dose-Finding Study for Extremely Low-Birth-Weight Infants: A Randomized Clinical Trial. JAMA Pediatr. 2020;174(7):649–56. [Cited 2020 Jul 6] Available from: .
    1. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:1–42. doi: 10.1136/bmj.e7586.
    1. Instruction for Use - Intralipid ® 20 % Container [package insert]. Deerfield: Baxter Healthcare Corporation; 2015.
    1. Morioka I. Hyperbilirubinemia in preterm infants in Japan: New treatment criteria. Pediatr Int. 2018;60(8):684–690. doi: 10.1111/ped.13635.
    1. Shimabuku R, Nakamura H. Total and unbound bilirubin determination using an automated peroxidase micromethod. Kobe J Med Sci. 1982;28(2):91–104.
    1. Fenton TR, Nasser R, Eliasziw M, Kim JH, Bilan D, Sauve R. Validating the weight gain of preterm infants between the reference growth curve of the fetus and the term infant. BMC Pediatr. 2013;13(1).
    1. Morioka I, Nakamura H. Treatment criteria for infants with hyperbilirubinemia in Japan. Semin Perinatol. 2021;45(1):151352. 10.1016/j.semperi.2020.151352.
    1. Huber AH, Zhu B, Kwan T, Kampf JP, Hegyi T, Kleinfeld AM. Fluorescence Sensor for the Quantification of Unbound Bilirubin Concentrations. 2012; [Cited 2020 Jul 6]. .
    1. Richardson DK, Corcoran JD, Escobar GJ, Lee SK. SNAP-II and SNAPPE-II: Simplified newborn illness severity and mortality risk scores. J Pediatr. 2001;138(1):92–100. doi: 10.1067/mpd.2001.109608.
    1. Lasky RE, Rupert A, Waller M. Reproducibility of auditory brain-stem evoked responses as a function of the stimulus, scorer and subject. Electroencephalogr Clin Neurophysiol Evoked Potentials. 1987;68(1):45–57. doi: 10.1016/0168-5597(87)90069-4.
    1. Michalec D. Bayley Scales of Infant Development: Third Edition. In: Goldstein S, Naglieri JA, editors. Encyclopedia of Child Behavior and Development. Boston, MA: Springer US; 2011. p. 215.10.1007/978-0-387-79061-9_295.
    1. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997;39(4):214–23. 10.1111/j.1469-8749.1997.tb07414.x.
    1. Hegyi T, Kathiravan S, Stahl GE, Huber AH, Kleinfeld A. Unbound free fatty acids from preterm infants treated with intralipid decouples unbound from total bilirubin potentially making phototherapy ineffective. Neonatology. 2013;104(3):184–187. doi: 10.1159/000349995.
    1. Ponton CW, Moore JK, Eggermont JJ. Auditory brain stem response generation by parallel pathways: differential maturation of axonal conduction time and synaptic transmission. Ear Hear. 1996;17(5):402–410. doi: 10.1097/00003446-199610000-00006.
    1. Watchko JF, Jeffrey Maisels M. The enigma of low bilirubin kernicterus in premature infants: Why does it still occur, and is it preventable? Semin Perinatol. 2014;38(7):397–406.10.1053/j.semperi.2014.08.002.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren